History of NHT
Filters :
Filters :
NH TherAguix Appoints Jean-Philippe DEL as Chief Finance Officer2023
NH TherAguix appoints Vincent Carrère as CEO – Géraldine Le Duc (co-founder) becomes COO/CSO and member of the Board.2023
December – Ph.D defence of Désirée Tannous (CIFRE IGR-NHT) and of Clara Diaz (collaboration Montpellier University)2022
October – Thesis defense of Dr. Paul Rocchi as the first NHT-funded PhD student2022
September – Recruitment of Olivier de Beaumont as Chief Medical Officer.2022
March – First patient enrolled in clinical trial Nano-GBM targeting glioblastoma with institut Jean PERRIN in Clermont-Ferrand, France.2022
January – Obtainment of the ODD from the EMA for the treatment of pancreatic cancer with AGuIX®2022
December – Obtainment of the ODD from the EMA for the treatment of glioblastoma with AGuIX®2021
October – First patients enrolled in NanoBrainMets and NanoSmart clinical trials at Dana-Farber Brigham Cancer Center, Boston (USA)2021
October – Prize Ernst & Young: “Entrepreneur de l’année, prix spécial du jury”.2021
Production of the fourth batch of human injectable drug manufactured by SANOFI/CARBOGEN AMCIS2021
May – Obtainment of the ODD from the US FDA for the treatment of glioblastoma with AGuIX®2021
April – Second publication about the First-In-Human trial NANORAD in Radiotherapy & Oncology2021
February – Obtainment of the ODD from the US FDA for the treatment of pancreatic cancer with AGuIX®2021
Internalization of MRI Data analysis knowledge and know how (arrival of Fabien Boux as MRI Engineer and support from Yannick Crémillieux as MRI expert)2021
Arrival of Michel Julien as Head of Chemistry Manufacturing and Control2020
Leverage of €6M of non dilutive funds performed including bank loans, BPI subsidies and academic grant (NIH, ANR)2020
Second patent with Harvard Medical School (MRI-Linac) and Grant NIH $3M related to the collaboration with Harvard Medical School2020
October – Investigational New Drug (IND) becomes active2020
Production of the third batch of human injectable drug manufactured by SANOFI/CARBOGEN AMCIS2020
Structuration of the Clinical Development unit – Recruitment of Markus Loeffler as Chief Medical Officer and Khalide Seddik as Clinical Operations Responsible2020
Final report of NANORAD Phase 1 clinical trial and start of NANORAD 2 multicentric Phase 2 clinical trial2019
Creation of Administrative & Financial unit (arrival of Caroline Cayre and Florence Cruz)2019
Appointment of Hervé Brailly as Chairman of the Supervisory Board2019
Series A funding (13M€) – BPI Innobio2, Arbevel, Omnes, Supernova2019
Prize Galien (MedStartUp) (New York) – Third prize for the “Best collaboration in the pharmaceutical or biotechnology industry in 2019” related to the collaboration with Dana Farber Cancer Institute2019
Prize IMPI awarded to ILM – Fennec Team (Olivier Tillement)2018
Review article on AGuIX® by François Lux et al. in The British Journal of Radiology2018
Production of the second batch of human injectable drug manufactured by CARBOGEN AMCIS2018
Prize “Business with Attitude” awarded to Géraldine Le Duc CEO (Entreprenariat féminin, Figaro Madame)2018
Start of NANOCOL Phase 1 clinical trial on cervical cancer at Institut Gustave Roussy2017
Research collaboration with Institut Gustave Roussy2017
Creation of Chemistry Manufacturing and Control unit (arrival of Tristan Doussineau) and beginning of partnership with SANOFI for API manufacturing2017
First Patent with Harvard Medical School2017
First-in-human injection of AGuIX® in the frame of NANORAD Phase 1 clinical trial on brain metastases at CHU Grenoble Alpes2016
Prize R2B Onco Cancéropole Lyon2016
Prizes « Tremplin Entreprises » Sénat -ESSEC & « Coup de Cœur » France Biotech2016
Research collaboration with Institut Lumière Matière2015
2015/2016 Inception of NHT by four co-founders Géraldine Le Duc, Olivier Tillement, François Lux, Sandrine Dufort2015
Production of the first batch of human injectable drug manufactured by CARBOGEN AMCIS2015
Princeps patent on AGuIX®2011
Design of a new optimized structure: the ultrasmall AGuIX nanoparticle2010
2005-2010: First demonstration of the radiosensitizing effect of gadolinium-based nanoconstructs2005
First radiosensitization studies on molecular and nanoparticular compounds containing high-Z elements2005